Last update 15 Nov 2024

Bortezomib

Last update 15 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid, Bortezomib (JAN/USAN/INN), N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide

+ [13]

Target

Proteasome

Mechanism

Proteasome inhibitors

Therapeutic Areas

NeoplasmsImmune System DiseasesCardiovascular Diseases+ [4]

Active Indication

Immunoglobulin Light-Chain AmyloidosisWaldenstrom MacroglobulinemiaMantle-Cell Lymphoma+ [16]

Inactive Indication

Acute Graft Versus Host DiseaseAcute Lymphoblastic LeukemiaAcute myeloid leukaemia with 11q23 abnormality+ [90]

Originator Organization

Millennium Pharmaceuticals, Inc.

Active Organization

Sun Pharmaceutical Industries (Europe) BV

Celgene Corp.Janssen Research & Development LLC

+ [20]

Inactive Organization

Johnson & Johnson Pharmaceutical Research & Development LLC

Genentech, Inc.

Novartis AG

+ [32]

Drug Highest PhaseApproved

First Approval Date

US (13 May 2003),

Multiple Myeloma

RegulationOrphan Drug (US), Accelerated Approval (US), Orphan Drug (JP), Orphan Drug (EU)

Structure

Molecular FormulaC19H25BN4O4

InChIKeyGXJABQQUPOEUTA-RDJZCZTQSA-N

CAS Registry179324-69-7

1,096

Clinical Trials associated with Bortezomib

NCT06015750 / Not yet recruitingPhase 4

An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)

The primary objective of this study is to evaluate the effect of immunosuppressive therapy (IST) in participants treated with asfotase alfa who demonstrate immune-mediated loss of effectiveness (LoE).

Start Date15 Jan 2025

Sponsor / Collaborator

Alexion Pharmaceuticals, Inc.

ChiCTR2400091491 / RecruitingEarly Phase 1IIT

A single-center, prospectivestudy of bortezomib in thetreatment of relapsed/refractoryacquired hemophilia

Start Date01 Dec 2024

Sponsor / Collaborator-

NCT06348147 / Not yet recruitingPhase 2IIT

An Attenuated Schedule Dara-RVd Induction for Patients With Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Stem Cell Transplantation

This Phase II hybrid decentralized trial will examine the effect of daratumumab-based quadruplet induction therapy administered at an attenuated schedule in subjects with newly diagnosed multiple myeloma (NDMM) who are eligible for standard-of-care autologous stem cell transplantation (ASCT). Daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVd) have recently become a standard induction regimen for patients with NDMM who are eligible for ASCT in the United States. As implemented in clinical trials, Dara-RVd involves twice weekly bortezomib administration, which is inconvenient for patients and may result in increased rates of limiting toxicity, such as peripheral neuropathy. Adoption of alternate schedules involving once-weekly bortezomib is common in real-world practice, however a paucity of prospective data supporting this practice exists.
This study examines the efficacy of an attenuated Dara-RVd schedule involving once-weekly bortezomib dosing.

Start Date01 Dec 2024

Sponsor / Collaborator

UNC Lineberger Comprehensive Cancer Center

100 Clinical Results associated with Bortezomib

100 Translational Medicine associated with Bortezomib

100 Patents (Medical) associated with Bortezomib

10,135

Literatures (Medical) associated with Bortezomib

31 Dec 2024·Hematology

The use of haploidentical stem cell transplant as an alternative donor source in patients with decreased access to matched unrelated donors

Review

Author: Litzow, Mark ; Graham, Christopher

INTRODUCTION:

The likelihood of finding HLA-matched unrelated donors for rare HLA types and non-white European ancestry continues to be a challenge with less than a 70% chance of finding a full match. Mismatched transplants continue to have high rates of transplant-related mortality. With the near-universal ability to find a haploidentical donor in families, haploidentical transplants have become of more critical importance in ethnic minority groups and patients with rare HLA types.

METHODS:

Data was collected through clinical trials, review articles, and case reports published in the National Library of Medicine.

RESULTS:

The use of improved lymphodepleting conditioning regimens, graft versus host disease (GVHD) prophylaxis using regimens such as post-transplant cyclophosphamide, mycophenolate, and tacrolimus have improved engraftment to nearly 100 percent and reduced transplant-related mortality to less than 20 percent. Attention to donor-specific antibodies (DSAs) with interventions using bortezomib, rituximab, and plasmapheresis has decreased graft failure rates.

CONCLUSION:

With improved prevention of GVHD with interventions such as post-transplant cyclophosphamide and management of DSAs, haploidentical transplants continue to improve transplant-related mortality (TRM) compared to patients who received matched-related donor transplants. While TRM continues to improve, ongoing research with haploidentical transplants will focus on improving graft and donor immunosuppression and identifying the best regimens to improve TRM without compromising relapse-free survival.

31 Dec 2024·OncoImmunology

Clinically relevant GABARAP deficiency abrogates bortezomib-induced immunogenic cell death in multiple myeloma

Article

Author: Zhao, Liwei ; Kroemer, Guido ; Kepp, Oliver ; Shen, Zhe

Recently, it was revealed that the high-risk, poor-prognosis downregulation of GABA type A receptor-associated protein (GABARAP) causes a defect in both autophagy and surface exposure of calreticulin (CALR) in multiple myeloma (MM) cells responding to bortezomib. Hence, GABARAP-defective MM cells fail to undergo immunogenic cell death.

31 Dec 2024·Hematology

Circular RNA_0003489 reflects unfavorable treatment response and shortened survival in newly diagnosed multiple myeloma patients who receive bortezomib-based induction therapy

Article

Author: Ran, Qijie ; Xie, Junjie ; Song, Senhua ; Xu, Biao

OBJECTIVES:

Circular RNA_0003489 (Circ_0003489) promotes multiple myeloma (MM) progression and bortezomib resistance in MM cells, while its potential as a biomarker in newly diagnosed MM (NDMM) patients is unclear. Thus, this study aimed to investigate the association of circ_0003489 expression with treatment response and survival in NDMM patients who received bortezomib-based induction therapy.

METHODS:

Bone marrow (BM) specimens from 85 NDMM patients at diagnosis or before treatment and from 15 donor controls during BM examination were retrieved in this retrospective study. Circ_0003489 derived from BM plasma cells was detected by reverse transcription-quantitative polymerase chain reaction and cut by quartile and median for further analysis.

RESULTS:

Circ_0003489 expression was increased in NDMM patients versus donor controls (P < 0.001). Circ_0003489 quartile was positively correlated with BM plasma cells (P = 0.040), international staging system (ISS) stage (P = 0.007), the revision of ISS stage (P = 0.003), beta-2-microglobulin (P = 0.011), and lactate dehydrogenase (P = 0.042) in NDMM patients. Increased circ_0003489 quartile was linked with a lower possibility of achieving complete response (P = 0.020) and partial response or better (P = 0.041) in NDMM patients. Elevated circ_0003489 expression cut by quartile (P = 0.020) and cut by median (P = 0.006) were linked with decreased progression-free survival (PFS) in NDMM patients. Increased circ_0003489 expression cut by median was associated with shortened overall survival (OS) in NDMM patients (P = 0.038). Meanwhile, higher circ_0003489 quartile independently forecasted poorer PFS (hazard ratio = 1.342, P = 0.045), but not OS in NDMM patients.

CONCLUSION:

Circ_0003489 expression is increased and reflects unfavorable treatment response and survival in NDMM patients who receive bortezomib-based induction therapy.

335

News (Medical) associated with Bortezomib

14 Nov 2024

·www.globenewswire.com

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination with VRd significantly improved progression-free survival, compared to standard-of-care VRd aloneIf approved, Sarclisa would be the first anti-CD38 therapy in the EU available for use in combination with VRd for adult patients with transplant-ineligible NDMM Paris, November 14, 2024. The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT). A final decision is expected in the coming months. Dietmar Berger, M.D., Ph.D.Chief Medical Officer, Global Head of Development at Sanofi“The positive CHMP opinion is an important step forward for people with transplant-ineligible newly diagnosed multiple myeloma for whom effective front-line therapy may improve long-term outcomes. If approved, this Sarclisa-based combination could establish a new standard-of-care treatment approach for patients in the EU, helping to address a critical care gap in multiple myeloma treatment, and reinforcing Sarclisa’s potential as the anti-CD38 therapy of choice.” In September 2024, the US Food and Drug Administration (FDA) approved Sarclisa in combination with VRd for the treatment of adult patients with NDMM who are not eligible for ASCT, representing the first global approval for Sarclisa in the first line setting. In addition, the FDA granted orphan drug exclusivity for Sarclisa in the approved indication. Sarclisa is currently approved in two indications for the treatment of certain adult patients with relapsed or refractory MM in more than 50 countries, including the US and EU. First positive global phase 3 study combining anti-CD38 therapy with VRd to significantly improve PFS versus VRd alone in transplant-ineligible NDMM supports CHMP decisionThe positive CHMP opinion is based on data from the IMROZ phase 3 study, which was presented at the American Society of Clinical Oncology 2024 annual meeting, European Hematology Association 2024 meeting, and published in The New England Journal of Medicine. IMROZ is the first global phase 3 study of a CD38 monoclonal antibody in combination with standard-of-care VRd to significantly improve progression-free survival (PFS) versus VRd alone. The safety and tolerability of Sarclisa observed was consistent with the established safety profile of Sarclisa and VRd with no new safety signals. About SarclisaSarclisa (isatuximab) is a CD38 monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity. CD38 is highly and uniformly expressed on the surface of MM cells, making it a target for antibody-based therapeutics such as Sarclisa. In the US, the non-proprietary name for Sarclisa is isatuximab-irfc, with irfc as the suffix designated in accordance with nonproprietary naming of biological products guidance for industry issued by the US FDA. Currently Sarclisa is approved in more than 50 countries, including the US and EU, across two indications; Sarclisa is approved under an additional indication in the US. In Europe, based on the ICARIA-MM phase 3 study, Sarclisa is approved in combination with pomalidomide and dexamethasone for the treatment of patients with relapsed refractory MM (RRMM) who have received ≥2 prior therapies, including lenalidomide and a proteasome inhibitor and who progressed on last therapy. Based on the IKEMA phase 3 study, Sarclisa is also approved in 50 countries in combination with carfilzomib and dexamethasone, including in the US for the treatment of patients with RRMM who have received 1–3 prior lines of therapy and in the European Union for patients with MM who have received at least 1 prior therapy. In the US, Sarclisa is also approved in combination with VRd as a first line treatment option for adult patients with NDMM who are not eligible for ASCT, based on the IMROZ phase 3 study. Sanofi continues to advance Sarclisa as part of a patient-centric clinical development program, which includes several phase 2 and phase 3 studies across the MM treatment continuum spanning six potential indications. In addition, the company is evaluating a subcutaneous administration method for Sarclisa in clinical studies. The safety and efficacy of Sarclisa has not been evaluated by any regulatory authority outside of its approved indications and methods of delivery. In striving to become the number one immunoscience company globally, Sanofi remains committed to advancing oncology innovation. Through focused strategic decisions the company has reshaped and prioritized its pipeline, leveraging its expertise in immunoscience to drive progress. Efforts are centered on difficult-to-treat cancers such as select hematologic malignancies and solid tumors with critical unmet needs, including multiple myeloma, acute myeloid leukemia, certain types of lymphomas, as well as gastrointestinal and lung cancers. For more information on Sarclisa clinical studies, please visit www.clinicaltrials.gov. About SanofiWe are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.comEvan Berland | +1 215 432 0234 | evan.berland@sanofi.comNicolas Obrist | + 33 6 77 21 27 55 | nicolas.obrist@sanofi.comVictor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.comTimothy Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.com Investor RelationsThomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.comAlizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.comArnaud Delépine | + 33 6 73 69 36 93 | arnaud.delepine@sanofi.comFelix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.comKeita Browne | + 1 781 249 1766 | keita.browne@sanofi.comNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.comTarik Elgoutni | + 1 617 710 3587 | tarik.elgoutni@sanofi.comThibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com Sanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Press Release

Phase 3Drug ApprovalASCOClinical ResultImmunotherapy

14 Nov 2024

·endpts.com

GSK makes case for Blenrep's return with new blood cancer survival data

GSK continues to stack up wins to support Blenrep’s comeback, as the company teased new survival data from a late-stage multiple myeloma trial on Thursday. In people with second-line or later relapsed or refractory disease, Blenrep combined with bortezomib and dexamethasone met the overall survival secondary endpoint in the DREAMM-7 trial versus standard of care daratumumab plus bortezomib and dexamethasone, according to a Thursday release . The UK drugmaker is gearing up to relaunch Blenrep in the US in the second half of 2025 after it pulled the drug from the market several years ago in the wake of a failed confirmatory trial in later lines of multiple myeloma. The company has filed data from both the DREAMM-7 and the DREAMM-8 trial of Blenrep combined with pomalidomide plus dexamethasone this year. According to DREAMM-7 topline results in February, the Blenrep regimen slashed the risk of disease progression or death by 59%. At the time, the company only said it had a “meaningful trend” in survival. The new DREAMM-7 data “underscore the potential for this Blenrep combination to extend the lives of patients,” GSK’s head of oncology R&D Hesham Abdullah said in the release. But details of the survival data will have to wait as the company will present them at the American Society of Hematology annual meeting in December. The drugmaker believes Blenrep could reach more than $3 billion in peak sales, mostly driven by the second-line patient population. It is looking to displace Johnson & Johnson’s anti-CD38 monoclonal antibody Darzalex as the second-line standard of care. Meanwhile, GSK plans to start Phase 3 studies comparing Blenrep with Darzalex in first-line multiple myeloma next year. So far this year, GSK has filed Blenrep in the US, Europe, Japan, the UK, Canada and Switzerland. In China, the combination of Blenrep plus bortezomib and dexamethasone has been granted breakthrough therapy designation.

Phase 3Clinical ResultBreakthrough TherapyASHPriority Review

14 Nov 2024

·firstwordpharma.com

Blenrep's resurrection bid gains momentum as GSK confirms new survival data

GSK on Thursday said that the BCMA-targeted antibody-drug conjugate Blenrep (belantamab mafodotin) significantly improved overall survival (OS) versus Johnson & Johnson's Darzalex (daratumumab) as a second-line or later treatment for relapsed or refractory multiple myeloma, marking the latest development in the drug's turnaround story."This is a statistically significant and clinically meaningful advancement for patients and potentially transformative for treatment," remarked Hesham Abdullah, global head for oncology R&D at GSK. "We look forward to sharing these data with health authorities and presenting the full results at next month’s American Society of Hematology (ASH) annual meeting."Back in February, GSK detailed results from the primary endpoint of the Phase III DREAMM-7 study, with Blenrep in combination with bortezomib and dexamethasone reducing the risk of disease progression or death by 59% compared to Darzalex plus bortezomib and dexamethasone, with median progression-free survival (PFS) in the two groups of 36.6 months and 13.4 months, respectively. At the time, the company also noted that a clinically meaningful OS trend had been observed, with Blenrep cutting the risk of death by 43%, although the data were not mature. On Thursday, GSK indicated that the the key secondary OS endpoint of the trial has now been met, with Blenrep significantly reducing the risk of death versus standard of care with Darzalex.Based on the earlier results from DREAMM-7, as well as those from the Phase III DREAMM-8 study, the pharma has submitted filings for Blenrep in a number of markets, including the US, EU and Japan.Blenrep was yanked from the US market in 2022 after it failed to show superiority over the combination of Bristol Myers Squibb's Pomalyst (pomalidomide) and low-dose dexamethasone in a confirmatory study of patients with relapsed or refractory multiple myeloma, with the drug meeting a similar fate in Europe.

Phase 3Clinical ResultASH

100 Deals associated with Bortezomib

External Link

KEGG	Wiki	ATC	Drug Bank
D03150	Bortezomib	L01XX32	DB00188

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Immunoglobulin Light-Chain Amyloidosis	JP	Janssen Pharmaceutical KK	20 Oct 2006
Waldenstrom Macroglobulinemia	JP	Janssen Pharmaceutical KK	20 Oct 2006
Mantle-Cell Lymphoma	EU	Janssen-Cilag International NV	26 Apr 2004
Mantle-Cell Lymphoma	IS	Janssen-Cilag International NV	26 Apr 2004
Mantle-Cell Lymphoma	LI	Janssen-Cilag International NV	26 Apr 2004
Mantle-Cell Lymphoma	NO	Janssen-Cilag International NV	26 Apr 2004
Multiple Myeloma	US	Takeda Pharmaceuticals U.S.A., Inc.	13 May 2003

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diffuse large B-cell lymphoma recurrent	Phase 3	IT	Janssen-Cilag Ltd.	04 Feb 2013
Diffuse large B-cell lymphoma recurrent	Phase 3	IT	Janssen Pharmaceutica NV	04 Feb 2013
Diffuse large B-cell lymphoma refractory	Phase 3	IT	Janssen Pharmaceutica NV	04 Feb 2013
Diffuse large B-cell lymphoma refractory	Phase 3	IT	Janssen-Cilag Ltd.	04 Feb 2013
Diffuse Large B-Cell Lymphoma	Phase 3	CH	Janssen-Cilag Ltd.	01 Apr 2011
Diffuse Large B-Cell Lymphoma	Phase 3	GB	Janssen-Cilag Ltd.	01 Apr 2011
B-Cell Lymphoma	Phase 3	US	Millennium Pharmaceuticals, Inc.	01 Mar 2006
B-Cell Lymphoma	Phase 3	US	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Mar 2006
B-Cell Lymphoma	Phase 3	CN	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Mar 2006
B-Cell Lymphoma	Phase 3	CN	Millennium Pharmaceuticals, Inc.	01 Mar 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2024	Not Applicable	Multiple Myeloma	-	Pomalidomide, Bortezomib, Dexamethasone	wblbtjglik(fkxwkllicm) = mezrtlulsk tjisybtcny (lxbizijusw ) View more	-	09 Dec 2024
REST (ASH2024)	Phase 2	Multiple Myeloma First line	51	Isatuximab-Bortezomib-Lenalidomide-Dexamethasone	jrbfheszza(boudnwbwpy) = quutrghpnu yhuckcokol (sfjzwnbbgc, 82 - 99) View more	Positive	09 Dec 2024
NCT03319667 (IMROZ, ASH2024)	Phase 3	Multiple Myeloma	446	Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd)	qwaaorkvve(flrsgdtshe) = pmeaqjokzt ghsvvipvlu (tlpwlnixbj ) View more	Positive	09 Dec 2024
ASH2024	Not Applicable	Waldenstrom Macroglobulinemia	-	Bortezomib+Ibrutinib/Rituximab	uzdogyfkim(ldfxwrczmt) = njncsxjaxm qvzgordltt (rzhzuunbsp ) View more	-	09 Dec 2024
NCT03617731 (GMMG-HD7, ASH2024)	Phase 3	Multiple Myeloma CD38	662	Isatuximab, Lenalidomide, Bortezomib, Dexamethasone	hvndnilkrw(omrsdxqzxm) = aavllaryvf lhobgdbyqe (hguhdbjejc, 95% CI 0.52 - 0.94) View more	Positive	09 Dec 2024
NCT03617731 (GMMG-HD7, ASH2024)	Phase 3	Multiple Myeloma CD38	662	Lenalidomide, Bortezomib, Dexamethasone	hvndnilkrw(omrsdxqzxm) = xgbvhwkqem lhobgdbyqe (hguhdbjejc, 95% CI 46 - 48) View more	Positive	09 Dec 2024
ASH2024	Not Applicable	Multiple Myeloma	-	Ixazomib-lenalidomide-dexamethasone (IRd)	sgufssfkik(gfbxafltyd) = Any grade TEAEs reported in ≥25% of pts were diarrhea (26%) in the 1−3 cycles group; PN not elsewhere classified (NEC; 34%), fatigue (34%), diarrhea (34%), and edema NEC (26%) in the 4−9 cycles group; and diarrhea (68%), PN NEC (53%), fatigue (42%), edema NEC (38%), arthralgia (35%), nausea (33%), and back pain (29%) in the >9 cycles group. ncebaoytag (wcbxnieamb ) View more	-	09 Dec 2024
ASH2024	Not Applicable	Multiple Myeloma	-	Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd)	mdjzhlyiwv(dvarpzmfdq) = imapiljnhz qmtrcckcwe (wmopshobvt ) View more	-	08 Dec 2024
ASH2024	Not Applicable	Multiple Myeloma	-	DVRd-DR	mdjzhlyiwv(dvarpzmfdq) = khxbttimea qmtrcckcwe (wmopshobvt ) View more	-	08 Dec 2024
ASH2024	Not Applicable	Multiple Myeloma	-	Daratumumab, Lenalidomide, Bortezomib, Dexamethasone (D-RVd)	bfbuklrbgc(xarpkayklb) = 82% qhmkjkxyww (hwdbqzkqkw ) View more	-	08 Dec 2024
CASTOR (ASH2024)	Phase 3	Multiple Myeloma	-	Daratumumab/bortezomib/dexamethasone (DVd)	iwgjpxaugd(icphpveqdd) = rbtcebtmsy rudkadsenj (usqothjqlq, 48.5 - 56.2) View more	Positive	08 Dec 2024
ASH2024	Not Applicable	Multiple Myeloma	-	Selinexor 40 mg QW + Lenalidomide 25mg + Dexamethasone 20mg	immgnyekrn(kpjgwxjsnu) = Grade 3 events included: Anxiety (N=1) neqbfbckpj (kgyecedsqw ) View more	-	07 Dec 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis